WuXi Biologics Reports Solid 2023 Annual Results - Thailand Business News

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million

Related Keywords

Dundalk ,Louth ,Ireland ,Worcester ,Massachusetts ,United States ,Germany ,Wuxi ,Jiangsu ,China ,Hong Kong ,Boston ,Wuppertal ,Nordrhein Westfalen ,Thailand ,Singapore ,American ,America ,Pharmadule Morimatsu ,Chris Chen ,Group Free Cash Flow ,Company For The Reporting Period ,Boston Research Service Center ,Amicus Therapeutics Inc ,International Society For Pharmaceutical Engineering ,Shareholders Of The Company ,Cayman Inc ,European Commission ,Thriving Research Business Achieved Remarkable Success ,Wuxi Biologics Cayman Inc ,Technology Platform Launched To Boost Development Strength ,Contract Research ,Manufacturing Organization ,Research Services Revenue Exceeded ,Group Singapore ,Hong Kong Stock Exchange ,Nasdaq ,Seasoned Talent Team ,Revenue Increased ,Profit Rose ,Yoy Growth ,Strong Momentum ,Commercial Manufacturing Revenue Grew ,Extended Partnerships ,Integrated Projects Set ,All Time High ,Underpin Sustainable ,Backlog Amounted ,Model Enabled Sustainable Long Term Growth ,Delivered Solid Revenue ,Integrated Projects ,Commercial Manufacturing Revenue Increased ,Talent Pool Enhanced ,Support Business ,Trend Sustained Across Various Geographic Markets ,New Modalities Emerged ,New Drivers ,Quality System ,Global Regulatory ,Wuxi Biologics Business System ,Initiatives Executed ,Improve Operational ,Start Any Project ,Wuxi Biologics ,Gross Profit Margin ,Net Profit Attributable ,Reporting Period ,Net Profit ,Adjusted Net Profit ,Earnings Per Share ,Free Cash Flow ,Main Board ,North American ,Dow Jones Sustainability ,World Index ,Emerging Markets Index ,Ecovadis Platinum Medal ,Sustainalytics Industry ,Regional Top Rated Company ,Commercial Manufacturing Projects Drive Future ,Amicus Therapeutics ,Premier Technology Platform Launched ,Boost Development ,Life Improving Biologics ,Strengthen Manufacturing ,Year Award ,International Society ,Pharmaceutical Engineering ,New Modalities ,Wuxi Vaccines ,Hong Kong Stock ,Long Term Business Strategy ,Science Based Targets ,United Nations Global ,North America ,Global Dual Sourcing ,Twelve Months Ended Dec ,Profit Attributable ,Wuxi Biologics Reports Solid ,Thailand Business ,